石药集团：帕妥珠单抗注射液的上市申请获国家药品监督管理局受理

Core Viewpoint - The announcement indicates that the application for the listing of the drug Pertuzumab injection, developed by the subsidiary of the company, has been accepted by the National Medical Products Administration of the People's Republic of China, targeting HER2-positive breast cancer [1] Group 1 - The drug Pertuzumab injection is classified under Category 3.3 of therapeutic biological products [1] - The indication for the drug is specifically for HER2-positive breast cancer [1]